dc.contributor
Institut Català de la Salut
dc.contributor
[Abad E, Sandoz J, Zadra I, Borredat P] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. [Romero G] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Urgel Solas J] Department of Medicine and Life Sciences, Universidad Pompeu Fabra, Barcelona, Spain. Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
ABAD, ETNA
dc.contributor.author
Sandoz, Jeremy
dc.contributor.author
Romero Sola, Gerard
dc.contributor.author
Zadra, Ivan
dc.contributor.author
Urgel-Solas, Julia
dc.contributor.author
Borredat, Pablo
dc.date.accessioned
2025-10-25T05:38:00Z
dc.date.available
2025-10-25T05:38:00Z
dc.date.issued
2024-05-22T12:19:55Z
dc.date.issued
2024-05-22T12:19:55Z
dc.date.issued
2024-04-29
dc.identifier
Abad E, Sandoz J, Romero G, Zadra I, Urgel-Solas J, Borredat P, et al. The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability. J Exp Clin Cancer Res. 2024 Apr 29;43(1):127.
dc.identifier
https://hdl.handle.net/11351/11488
dc.identifier
10.1186/s13046-024-03045-4
dc.identifier.uri
http://hdl.handle.net/11351/11488
dc.description.abstract
Aneuploidy; Cancer; Genomic instability
dc.description.abstract
Aneuploidía; Cáncer; Inestabilidad genómica
dc.description.abstract
Aneuploïdia; Càncer; Inestabilitat genòmica
dc.description.abstract
Background
TP53, the most frequently mutated gene in human cancers, orchestrates a complex transcriptional program crucial for cancer prevention. While certain TP53-dependent genes have been extensively studied, others, like the recently identified RNF144B, remained poorly understood. This E3 ubiquitin ligase has shown potent tumor suppressor activity in murine Eμ Myc-driven lymphoma, emphasizing its significance in the TP53 network. However, little is known about its targets and its role in cancer development, requiring further exploration. In this work, we investigate RNF144B's impact on tumor suppression beyond the hematopoietic compartment in human cancers.
Methods
Employing TP53 wild-type cells, we generated models lacking RNF144B in both non-transformed and cancerous cells of human and mouse origin. By using proteomics, transcriptomics, and functional analysis, we assessed RNF144B's impact in cellular proliferation and transformation. Through in vitro and in vivo experiments, we explored proliferation, DNA repair, cell cycle control, mitotic progression, and treatment resistance. Findings were contrasted with clinical datasets and bioinformatics analysis.
Results
Our research underscores RNF144B's pivotal role as a tumor suppressor, particularly in lung adenocarcinoma. In both human and mouse oncogene-expressing cells, RNF144B deficiency heightened cellular proliferation and transformation. Proteomic and transcriptomic analysis revealed RNF144B's novel function in mediating protein degradation associated with cell cycle progression, DNA damage response and genomic stability. RNF144B deficiency induced chromosomal instability, mitotic defects, and correlated with elevated aneuploidy and worse prognosis in human tumors. Furthermore, RNF144B-deficient lung adenocarcinoma cells exhibited resistance to cell cycle inhibitors that induce chromosomal instability.
Conclusions
Supported by clinical data, our study suggests that RNF144B plays a pivotal role in maintaining genomic stability during tumor suppression.
dc.description.abstract
This work was supported by grants and fellowships from the Spanish Ministry of Science and Development Grant to A.J. (PID2021-127710OB-I00) and “La Caixa” foundation (51110009). A.J. is supported by Ramon y Cajal Research Fellowship (RYC2018-025244-I). I.Z. is funded by an AECC Postdoctoral Fellowship (POSTD234858ZADR), and J.U. by La Caixa PhD Scholarship (LCF/BQ/DR22/11950019). This work was made possible through the “Unidad de Excelencia María de Maeztu'' funded by the MCIN and AEI (CEX2018-000792-M).
dc.format
application/pdf
dc.publisher
BioMed Central
dc.relation
Journal of Experimental & Clinical Cancer Research;43(1)
dc.relation
https://doi.org/10.1186/s13046-024-03045-4
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Anomalies cromosòmiques
dc.subject
Pulmons - Càncer - Aspectes genètics
dc.subject
Proteïnes supressores de tumors
dc.subject
DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Adenocarcinoma of Lung
dc.subject
Other subheadings::Other subheadings::Other subheadings::/genetics
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Poly-ADP-Ribose Binding Proteins::Tumor Suppressor Protein p53
dc.subject
DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Genomic Instability
dc.subject
ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::adenocarcinoma de pulmón
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/genética
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas transportadoras::proteínas de unión a poli-ADP-ribosa::proteína supresora de tumor p53
dc.subject
ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inestabilidad genómica
dc.title
The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion